Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Cash from Financing Activities (2021 - 2024)

Trinity Biotech's Cash from Financing Activities history spans 4 years, with the latest figure at $1.8 million for Q4 2024.

  • On a quarterly basis, Cash from Financing Activities rose 202.21% to $1.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$4.2 million, a 49.64% increase, with the full-year FY2025 number at $12.1 million, down 58.17% from a year prior.
  • Cash from Financing Activities hit $1.8 million in Q4 2024 for Trinity Biotech, up from -$1.8 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for TRIB hit a ceiling of $1.8 million in Q4 2024 and a floor of -$3.6 million in Q4 2021.
  • Historically, Cash from Financing Activities has averaged -$1.7 million across 4 years, with a median of -$2.1 million in 2022.
  • Biggest five-year swings in Cash from Financing Activities: dropped 2.49% in 2023 and later soared 202.21% in 2024.
  • Tracing TRIB's Cash from Financing Activities over 4 years: stood at -$3.6 million in 2021, then skyrocketed by 48.56% to -$1.8 million in 2022, then increased by 4.28% to -$1.8 million in 2023, then soared by 202.21% to $1.8 million in 2024.
  • Business Quant data shows Cash from Financing Activities for TRIB at $1.8 million in Q4 2024, -$1.8 million in Q4 2023, and -$2.4 million in Q3 2023.